A ranar 30 ga Yuni, maganin hana MET na Avistone Vebreltinib wanda aka samar da kansa ya sami amincewar sharaɗi daga Hukumar Kayayyakin Lafiya ta Ƙasa (NMPA) ta ƙasar Sin don magance marasa lafiya da suka kamu da cutar kansar huhu ta hanyar gida ko kuma waɗanda suka kamu da cutar kansar huhu (NSCLC) wadda ke ɗauke da ƙara girman MET. Wannan ya nuna alama ta uku da aka amince da ita ga Vebreltinib a ƙasar Sin kuma magani na farko da aka amince da shi a duniya musamman ga marasa lafiya da aka ƙara girman NSCLC na MET.
Amincewar Vebreltinib a China don wannan sabon alama - maganin marasa lafiya da suka kamu da cutar kansar huhu ta hanyar da ba ta da ƙarfi ko kuma ta hanyar ƙwayoyin cuta marasa ƙanana (NSCLC) waɗanda ke ɗauke da ƙara yawan MET - ya dogara ne akan kyakkyawan sakamako daga Cohort 2 da Cohort 3 na binciken KUNPENG (NCT04258033).
Ƙungiyar 2 galibi ta yi rajistar marasa lafiya da aka yi wa magani a baya tare da NSCLC mai ƙarfin MET waɗanda suka gaza a maganin gargajiya (gami da maganin chemotherapy mai tushen platinum), yayin da ƙungiyar 3 ta haɗa da marasa lafiya waɗanda ba su da ƙwarewa a magani tare da NSCLC mai ƙarfin MET waɗanda suka ƙi maganin chemotherapy.
An yi wa jimillar marasa lafiya 86 da suka kamu da cutar NSCLC mai tsanani a yankinsu ko kuma waɗanda suka kamu da cutar a cikin rukuni biyu (33 a cikin rukuni na 2 da 53 a cikin rukuni na 3). Sakamakon binciken ya nuna jimlar ƙimar amsawar da aka samu ta hanyar da ba ta dace ba (ORR) na 48.8%, ƙimar kula da cututtuka (DCR) na 77.9%, matsakaicin tsawon lokacin amsawa (DoR) na watanni 12.1, matsakaicin rayuwa ba tare da ci gaba ba (PFS) na watanni 7.4, da matsakaicin rayuwa gaba ɗaya (OS) na watanni 13.9.
A cikin ƙungiyar 2 (marasa lafiya 33 da aka yi wa magani a baya), ORR ya kasance 48.5%, DCR ya kasance 78.8%, matsakaicin DoR shine watanni 11.0, matsakaicin PFS shine watanni 6.2, kuma matsakaicin OS shine watanni 11.7.
A cikin ƙungiyar 3 (marasa lafiya 53 waɗanda ba su da magani), ORR ya kasance 49.1%, DCR ya kasance 77.4%, matsakaicin DoR shine watanni 12.1, matsakaicin PFS shine watanni 8.3, kuma matsakaicin OS shine watanni 15.5.
A cikin binciken KUNPENG, Kwamitin Bita Mai Zaman Kanta (IRC) ya tantance marasa lafiya 21 da suka kamu da cutar kwakwalwa ta asali. Daga cikin waɗannan, 10 sun sami amsoshi na ɓangare (PR), wanda ya haifar da ORR na 47.6%, DCR na 85.7%, da kuma matsakaicin DoR na watanni 11.0. Bugu da ƙari, matsakaicin PFS da OS sun kasance watanni 8.3 da watanni 14.7, bi da bi.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Lokacin Saƙo: Yuli-08-2025